40%的澳洲和新西兰公司无视皮肤癌风险评估、承担风险和数百万生产力损失。 40% of Aussie and NZ firms ignore skin cancer risk assessments, risking liability and millions in lost productivity.

一份新的白皮书显示,40%的澳大利亚和新西兰组织从未评估过雇员皮肤癌的风险,尽管它们承认有照顾责任,使主任面临责任。 A new whitepaper reveals that 40% of Australian and New Zealand organizations never assess employee skin cancer risks despite acknowledging a duty of care, exposing directors to liability. 未经处理的皮肤癌可能使新西兰26年的生产力损失6.48亿新西兰元,澳大利亚的损失预计会更高。 Untreated skin cancer could cost New Zealand $648 million in productivity over 26 years, with higher losses expected in Australia. 早期发现改善了生存——在0阶段为98%,而在高级阶段为24%——每年每雇员100-200美元的筛查费用远远低于600美元的一个缺勤日。 Early detection improves survival—98% at Stage 0 versus as low as 24% at advanced stages—and annual screenings costing $100–200 per employee are far cheaper than one missed workday at $600. 报告敦促各公司将皮肤检查视为卫生和安全以及环境、社会和公司治理标准规定的一项核心义务,要求进行正式风险评估、诊断工具和可衡量的结果。 The report urges companies to treat skin checks as a core duty under health and safety and ESG standards, requiring formal risk assessments, diagnostic tools, and measurable outcomes. MoleMap有超过25年的经验和53+诊所,提供工作场所筛查方案,以支持合规和雇员健康。 MoleMap, with over 25 years of experience and 53+ clinics, offers workplace screening programs to support compliance and employee health.